Skip to main content
SpringerLink
Log in

Current Treatment for chronic hepatitis C

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

The number one choice for treatment of chronic hepatitis C is the combination of once weekly subcutaneous pegylated interferon plus daily oral ribavirin. The duration of treatment and dose of ribavirin must be tailored to the hepatitis C virus (HCV) genotype. Patients infected with HCV genotype 1 should be treated for 48 weeks with a standard dosage of ribavirin (1000 or 1200 mg/d). This ribavirin dosage regimen is ’off-label’ when used in conjunction with pegylated interferon alfa-2b (12 kD). The approved dosage for use in combination with this agent is 800 mg daily. The appropriate duration of treatment and dosage of ribavirin for patients infected with HCV genotype 2 or 3 differs depending on the pegylated interferon that is chosen. It is important to note that the treatment paradigm for these individuals is quickly evolving. When using peginterferon alfa-2a (40 kD) in patients with HCV genotype 2 or 3, the duration of treatment should be 24 weeks in combination with a low dose of ribavirin (800 mg/d). When using pegylated interferon alfa-2b (12 kD) in patients infected with HCV genotype 2 or in patients infected with genotype 3 and hepatitis C virus RNA less than 600,000 IU/mL, the duration of treatment should be 24 weeks. However, recent data suggest such treatment may not be optimal for patients infected with HCV genotype 3 and hepatitis C virus RNA at levels greater than or equal to 600,000 IU/mL; treatment duration may need to be greater than 24 weeks. When using pegylated interferon alfa-2b (12 kD) in patients infected with HCV genotype 3 and high viral load, the optimal dosage of ribavirin appears to be 800 to 1400 mg/d based on bodyweight.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975–982. Randomized, controlled, multinational phase III registration trial. The combination of peginterferon alfa-2a (40 kD) plus ribavirin was significantly more effective than conventional interferon plus ribavirin or peginterferon alfa-2a (40 kD) monotherapy

    Article  PubMed  CAS  Google Scholar 

  2. Hadziyannis SJ, Sette H, Morgan TR, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140: 346–355. Randomized, controlled, multinational phase III registration trial of peginterferon alfa-2a (40 kD) plus ribavirin that employed an innovative 2 × 2 factorial design. The study examined the effect of treatment duration and ribavirin dose on SVR rates according to HCV genotype. Current treatment recommendations are based on the results of this trial.

    PubMed  CAS  Google Scholar 

  3. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358: 958–965. The first randomized, controlled, multinational phase III registration trial of a pegylated interferon plus ribavirin. The combination of pegylated interferon alfa-2b (12 kD) plus ribavirin was significantly more effective than conventional interferon plus ribavirin.

    Article  PubMed  CAS  Google Scholar 

  4. Zeuzem S, Diago M, Gane E, et al.: International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) [abstract 106]. Hepatology, 2003 384(Suppl 1): 208A.

    Article  Google Scholar 

  5. Ahmed A, Keeffe EB: Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 2004, 126: 1409–1415. Excellent recent review.

    Article  PubMed  Google Scholar 

  6. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39: 1147–1171. Recent evidence-based practice guideline endorsed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.

    Article  PubMed  Google Scholar 

  7. EASL International Consensus Conference on Hepatitis C. Paris, 26–28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999, 30:956–961.

  8. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10–12, 2002. Hepatology 2002, 36:S3-S20.

  9. Zeuzem S: Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004, 140: 370–381. Excellent recent review.

    PubMed  CAS  Google Scholar 

  10. Alberti A: Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed? J Hepatol 2004, 40: 1032–1035.

    Article  PubMed  CAS  Google Scholar 

  11. Zeuzem S, Hultcrantz R, Bourliere M, et al.: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004, 40: 993–999. Recent study that points to the most appropriate strategy for managing HCV genotype 2 or 3 patients with pegylated interferon alfa-2b (12 kD) plus ribavirin.

    Article  PubMed  CAS  Google Scholar 

  12. Jeffers LJ, Cassidy W, Howell CD, et al.: Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39: 1702–1708.

    Article  PubMed  CAS  Google Scholar 

  13. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350: 2265–2271. Recent study of pegylated interferon alfa-2b (12 kD) plus ribavirin that demonstrated that SVR rates are significantly lower in blacks than non-Hispanic whites.

    Article  PubMed  CAS  Google Scholar 

  14. Layden-Almer JE, Ribeiro RM, Wiley T, et al.: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37: 1343–1350.

    Article  PubMed  CAS  Google Scholar 

  15. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment [discussion 947]. Gastroenterology 2004, 126: 1015–1123.

    Article  PubMed  CAS  Google Scholar 

  16. McHutchison JG, Ware JE, Bayliss MS, et al.: The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001, 34: 140–147.

    Article  PubMed  CAS  Google Scholar 

  17. Reddy KR, Fried MW, Shiffman ML, et al.: The influence of cumulative exposure to combination peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin on sustained virologic response (SVR) rates in patients with genotype 1 chronic hepatitis C [abstract 505]. J Hepatol 2004, 40(suppl 1):149.

    Article  Google Scholar 

  18. Torriani FJ, Rodriguez-Torris M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, In press. Randomized controlled multinational phase III registration trial of peginterferon alfa-2a (40 kD) plus ribavirin in patients with HIV-HCV coinfection. The results are consistent with those of Fried et al. [1] and support extension of the chronic hepatitis C treatment paradigm to patients with HIV-HCV coinfection.

  19. Bronowicki J-P, Ouzan D, Asselah T, et al.: Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2a (40KD) (PEGASYS) alone versus peginterferon alfa-2a (40KD) plus ribavirin (COPEGUS) In naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2a (40KD) plus ribavirin: an open, multicenter, randomized trial [abstract 187]. Hepatology 2003, 38(4 Suppl 1):244A.

    Article  Google Scholar 

  20. Sánchez-Tapias JM, Diago M, Escartín P, et al.: Sustained virological response after prolonged treatment with peginterferon alfa-2a (40 kD) (PEGASYS) and ribavirin (COPEGUS) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: TeraViC-4 study [abstract 509]. J Hepatol 2004, 40(suppl 1):150.

    Article  Google Scholar 

  21. Jessner W, Gschwantler M, Steindl-Munda P, et al.: Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001, 358: 1241–1242.

    Article  PubMed  CAS  Google Scholar 

  22. Ferenci P, Fried MW, Chaneac M: A dynamic model to predict sustained virological response to combination peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) therapy in patients with chronic hepatitis C [abstract 995]. Hepatology 2003, 384(Suppl 1): 635A.

    Article  Google Scholar 

  23. Ferenci P, Brunner H, Nachbaur K, et al.: Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001, 34: 1006–1011.

    Article  PubMed  CAS  Google Scholar 

  24. Diago M, Romero-Gomez M, Crespo J, et al.: High-dose peginterferon alfa-2a (40 kD) (PEGASYS) and ribavirin (COPEGUS) in patients infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon alfa and ribavirin [abstract 1207]. Hepatology 2003, 38: 740A.

    Article  Google Scholar 

  25. Afdhal NH, Dieterich DT, Pockros PJ, et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126: 1302–1311.

    Article  PubMed  CAS  Google Scholar 

  26. Coon JT, Ernst E: Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J Hepatol 2004, 40: 491–500.

    Article  PubMed  Google Scholar 

  27. Ware JE, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The interventional therapy group. Hepatology 1999, 30: 550–555.

    Article  PubMed  Google Scholar 

  28. Bernstein D, Kleinman L, Barker CM, et al.: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35: 704–708.

    Article  PubMed  Google Scholar 

  29. Rasenack J, Zeuzem S, Feinman SV, et al.: Peginterferon alpha-2a (40 kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003, 21: 341–349.

    Article  PubMed  CAS  Google Scholar 

  30. Hassanein T, Cooksley G, Sulkowski M, et al.: The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004, 40: 675–681.

    Article  PubMed  CAS  Google Scholar 

  31. Marcellin P, Boyer N, Gervais A, et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127: 875–881.

    PubMed  CAS  Google Scholar 

  32. Poynard T, Ratziu V, Charlotte F, et al.: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34: 730–739.

    Article  PubMed  CAS  Google Scholar 

  33. Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122: 1303–1313.

    Article  PubMed  CAS  Google Scholar 

  34. Camma C, Di Bona D, Schepis F, et al.: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004, 39: 333–342.

    Article  PubMed  CAS  Google Scholar 

  35. Camma C, Di Marco V, Lo Iacono O, et al.: Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998, 28: 531–537.

    Article  PubMed  CAS  Google Scholar 

  36. Yoshida H, Arakawa Y, Sata M, et al.: Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002, 123: 483–491.

    Article  PubMed  CAS  Google Scholar 

  37. Imazeki F, Yokosuka O, Fukai K, Saisho H: Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003, 38: 493–502.

    Article  PubMed  CAS  Google Scholar 

  38. Coverdale SA, Khan MH, Byth K, et al.: Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004, 99: 636–644.

    Article  PubMed  CAS  Google Scholar 

  39. Berg T, Kronenberger B, Hinrichsen H, et al.: Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 2003, 37: 1359–1367.

    Article  PubMed  CAS  Google Scholar 

  40. Ferenci P, Formann E, Gschwantler M, et al.: Prospective evaluation of the 24 hour interferon (IFN) induced decline in hepatitis C virus genotype 1 load to predict sustained virologic response (SVR) to peginterferon-alfa2a/ ribavirin combination therapy with or without Amantadine [abstract 476]. J Hepatol 2004, 40(Suppl 1):141.

    Article  Google Scholar 

  41. Gish R, Arora S, Nelson D, et al.: Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients [abstract 479]. J Hepatol 2004, 40(Suppl 1):141.

    Article  Google Scholar 

  42. Nevens F, Roskams T, Van Vlierberghe H, et al.: A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003, 38: 1289–1296.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine IV, Medical University of Vienna, Allgemeines Krankenhaus, Währinger Gürtel 18-20, A 1090, Wien, Austria

    Peter Ferenci MD

Authors
  1. Peter Ferenci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferenci, P. Current Treatment for chronic hepatitis C. Curr Treat Options Gastro 7, 491–499 (2004). https://doi.org/10.1007/s11938-004-0008-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-004-0008-2

Keywords

Search

Navigation